Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zometa dosing schedules for bone mineral density during androgen deprivation therapy in non-metastatic prostate cancer
2005-004765-42Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of zoledronic acid in osteoporosis and prostate cancer (PCa) (2 arms), sponsored by Novartis. Primary endpoint: Percentage change in lumbar spine bone mineral density. Started Mar 2006; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosisprostate cancer (PCa)
Beyond the preview
Go deeper on 2005-004765-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004765-42.